United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate tablets are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in: - pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression [see warnings ] . - patients with diarrhea associated with pseudomembranous enterocolitis (clostridium difficile ) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis [see warnings ] . - patients with known hypersensitivity to diphenoxylate or atropine. - patients with obstructive jaundice. diphenoxylate hydrochloride and atropine sulfate is classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not

United States - English - NLM (National Library of Medicine)

chartwell rx, llc - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate tablets are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in: - pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression (see warnings ). - patients with diarrhea associated with pseudomembranous enterocolitis ( clostridium difficile ) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis (see warnings ). - patients with known hypersensitivity to diphenoxylate or atropine. - patients with obstructive jaundice. controlled substance diphenoxylate hydrochloride and atropine sulfate tablets are classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. drug abuse and depe

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride 2.5 mg - lomotil is indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. lomotil is contraindicated in: lomotil is classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self-administration. a dose of 100 to 300 mg/day, which is equivalent to 40 to 120 tablets, administered to humans for 40 to 70 days, produced opiate withdrawal symptoms. since addiction to diphenoxylate hydrochlo

United States - English - NLM (National Library of Medicine)

direct_rx - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate tablets usp are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in: • pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression (see warnings). • patients with diarrhea associated with pseudomembranous enterocolitis (clostridium difficile) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis (see warnings). • patients with known hypersensitivity to diphenoxylate or atropine. • patients with obstructive jaundice. controlled substance diphenoxylate hydrochloride and atropine sulfate tablets are classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. drug abuse and dependence in do

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate tablets are effective as adjunctive therapy in the management of diarrhea. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in patients with - known hypersensitivity to diphenoxylate or atropine, - obstructive jaundice, - diarrhea associated with pseudomembranous enterocolitis or enterotoxin-producing bacteria. diphenoxylate hydrochloride and atropine sulfate tablets are classified as a schedule v controlled substance. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochlor

United States - English - NLM (National Library of Medicine)

bayshore pharmaceuticals, llc - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate tablets are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in: - pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression (see warnings ). - patients with diarrhea associated with pseudomembranous enterocolitis (clostridium difficile ) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis (see warnings ). - patients with known hypersensitivity to diphenoxylate or atropine. - patients with obstructive jaundice. diphenoxylate hydrochloride and atropine sulfate tablets are classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self-administration. a dose of 100 to 300 mg/day, which is equivalent to 40 to 120 tablets, administered to humans for 40 to 70 days, produced opiate withdrawal symptoms. since addiction to diphenoxylate hydrochloride is possible at high doses, the recommended dosage should not be exceeded.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate is indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate is contraindicated in: - pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression (see warnings ). - patients with diarrhea associated with pseudomembranous enterocolitis ( clostridium difficile ) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis (see warnings ). - patients with known hypersensitivity to diphenoxylate or atropine. - patients with obstructive jaundice. diphenoxylate hydrochloride and atropine sulfate is classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self-administration. a dose of 100 to 300 mg/day, which is equivalent to 40 to 120 tablets, administered to humans for 40 to 70 days, produced opiate withdrawal symptoms. since addiction to diphenoxylate hydrochloride is possible at high doses, the recommended dosage should not be exceeded.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate tablets are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in: - pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression (see warnings ). - patients with diarrhea associated with pseudomembranous enterocolitis (clostridium difficile) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis (see warnings ). - patients with known hypersensitivity to diphenoxylate or atropine. - patients with obstructive jaundice. controlled substance: diphenoxylate hydrochloride and atropine sulfate tablets are classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. drug abuse and dependence: in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self- administration. a dose of 100 to 300 mg/day, which is equivalent to 40 to 120 tablets, administered to humans for 40 to 70 days, produced opiate withdrawal symptoms. since addiction to diphenoxylate hydrochloride is possible at high doses, the recommended dosage should not be exceeded.

United States - English - NLM (National Library of Medicine)

direct rx - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride is effective as adjunctive therapy in the management of diarrhea. diphenoxylate hydrochloride is contraindicated in patients with: known hypersensitivity to diphenoxylate or atropine. obstructive jaundice. diarrhea associated with pseudomembranous enterocolitis or enterotoxin-producing bacteria. controlled substance diphenoxylate hydrochloride is classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. drug abuse and dependence in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochl

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride is effective as adjunctive therapy in the management of diarrhea. diphenoxylate hydrochloride is contraindicated in patients with: known hypersensitivity to diphenoxylate or atropine. obstructive jaundice. diarrhea associated with pseudomembranous enterocolitis or enterotoxin-producing bacteria. controlled substance diphenoxylate hydrochloride is classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. drug abuse and dependence in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly